JP2020512153A - 閉ループインスリン管理システムの最大投与量の維持 - Google Patents
閉ループインスリン管理システムの最大投与量の維持 Download PDFInfo
- Publication number
- JP2020512153A JP2020512153A JP2019553969A JP2019553969A JP2020512153A JP 2020512153 A JP2020512153 A JP 2020512153A JP 2019553969 A JP2019553969 A JP 2019553969A JP 2019553969 A JP2019553969 A JP 2019553969A JP 2020512153 A JP2020512153 A JP 2020512153A
- Authority
- JP
- Japan
- Prior art keywords
- rate
- insulin
- delivery
- basal
- delivery rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 354
- 102000004877 Insulin Human genes 0.000 title claims abstract description 177
- 108090001061 Insulin Proteins 0.000 title claims abstract description 177
- 229940125396 insulin Drugs 0.000 title claims abstract description 177
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 64
- 239000008103 glucose Substances 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 48
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 22
- 238000001802 infusion Methods 0.000 claims abstract description 14
- 238000007726 management method Methods 0.000 claims abstract description 13
- 238000012377 drug delivery Methods 0.000 claims description 45
- 238000004422 calculation algorithm Methods 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 238000005259 measurement Methods 0.000 claims description 8
- 238000010586 diagram Methods 0.000 abstract description 4
- 230000001052 transient effect Effects 0.000 description 17
- 238000004891 communication Methods 0.000 description 14
- 238000012545 processing Methods 0.000 description 13
- 230000002218 hypoglycaemic effect Effects 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- 208000013016 Hypoglycemia Diseases 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 238000013507 mapping Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010070070 Hypoinsulinaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000035860 hypoinsulinemia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- General Business, Economics & Management (AREA)
- Biophysics (AREA)
- Business, Economics & Management (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Physiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Optics & Photonics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims (13)
- 閉ループインスリン管理システムの最大インスリン送達速度を決定するための方法であって、
(a)コントローラを有する薬物送達装置を提供することと、
(b)前記コントローラによって、
(i)一時的基礎インスリン送達がユーザーに送達されているかどうかを判定すること、及び
(ii)送達の総基礎速度(TBR)が、送達の既定の基礎速度(DBR)未満であるかどうかを判定することにより最大インスリン送達速度(MR)を計算することと、
(c)前記送達の総基礎速度が前記送達の既定の基礎送達速度未満であるとき、前記コントローラによって、前記最大インスリン送達速度(MR)を、前記総基礎送達速度のあるパーセンテージ、つまりMR=x% TBRとして計算し、設定することと、
(d)前記薬物送達装置によって、前記計算された最大インスリン送達速度に従ってインスリンを送達することと、を含む、方法。 - (e)拡張インスリンボーラス量が、拡張ボーラス送達速度でユーザーに送達されているかどうかを判定することと、
(f)前記コントローラによって、前記最大インスリン送達速度(MR)を、前記総基礎送達速度のあるパーセンテージ+前記拡張ボーラス送達速度、つまりMR=x%(TBR)+EBRとして計算し、設定することと、
(g)前記薬物送達装置によって、前記計算された最大インスリン送達速度に従ってインスリンを送達することと、更に含む、請求項1に記載の方法。 - 前記最大送達速度を計算することは、モデル予測制御アルゴリズムによって実行される、請求項1に記載の方法。
- x%は一定である、請求項3に記載の方法。
- 前記最大インスリン送達速度は、前記基礎速度の300%である、請求項1に記載の方法。
- 閉ループインスリン管理システムの最大インスリン送達速度を決定するための方法であって、
(a)コントローラを有する薬物送達装置を提供することと、
(b)前記コントローラによって、
(i)既定の基礎インスリン送達速度(DBR)を決定すること、及び、
(ii)最大インスリン送達速度(MR)を、前記既定の基礎送達速度(DBR)のあるパーセンテージ、つまりMR=(x% DBR)として計算することにより、前記最大インスリン送達速度(MR)を計算することと、
(c)前記薬物送達装置によって、前記計算された最大インスリン送達速度に従ってインスリンを送達することと、を含む、方法。 - 前記コントローラによって、拡張インスリンボーラス送達が拡張ボーラス送達速度(EBR)でユーザーに送達されているときを判定することと、
前記拡張インスリンボーラスが前記ユーザーに送達されているとき、前記コントローラによって、前記最大インスリン送達速度(MR)を、前記既定の基礎送達速度(DBR)のあるパーセンテージ+前記拡張ボーラス送達速度の量、つまりMR=(x% DBR)+EBRとして計算することと、を更に含む、請求項6に記載の方法。 - 一時的基礎インスリン送達がユーザーに送達されているときを判定することと、
前記コントローラを介して、送達の総基礎速度(TBR)が、送達の既定の基礎速度(DBR)未満であるかどうかを判定することと、を更に含む、請求項6に記載の方法。 - 前記送達の総基礎速度が前記送達の既定の基礎送達速度未満であるとき、前記コントローラによって、前記最大インスリン送達速度(MR)を、前記総基礎送達速度のあるパーセンテージ、つまりMR=x% TBRとして計算し、設定することを更に含む、請求項8に記載の方法。
- 前記送達の総基礎速度(TBR)が前記送達の既定の速度(DBR)以上であるとき、前記一時的基礎インスリン送達を無視し、前記コントローラによって、前記最大インスリン送達速度(MR)を、前記既定の基礎送達速度(DBR)のあるパーセンテージ、つまりMR=(x% DBR)として計算し、設定することを更に含む、請求項8に記載の方法。
- 閉ループインスリン管理システムの最大インスリン送達速度を決定するための方法であって、
(a)コントローラを有する薬物送達装置を提供することと、
(b)前記コントローラによって、
(i)拡張インスリンボーラス送達が拡張ボーラス送達速度(EBR)でユーザーに送達されているときを判定すること、及び
(ii)前記最大インスリン送達速度(MR)を、既定の基礎送達速度(DBR)のあるパーセンテージ+前記拡張ボーラス送達速度の量、つまりMR=(x% DBR)+EBRとして計算することによって、前記最大インスリン送達速度(MR)を計算することと、
(c)前記薬物送達装置によって、前記計算された最大インスリン送達速度に従ってインスリンを送達することと、を含む、方法。 - 糖尿病を管理するためのシステムであって、
グルコース測定データの形態で各間隔でユーザーの血糖値を提供するように構成されている連続グルコースモニタと、
インスリンを送達するためのインスリン注入ポンプと、
前記ポンプ及び前記グルコースモニタに動作可能に連結されているコントローラであって、前記コントローラは、前記連続グルコースモニタからの以前のグルコース測定データに基づいて少なくとも1つの将来のグルコース値を予測し、基礎インスリン送達速度、一時的基礎インスリン送達速度、拡張ボーラス、又はこれらの組み合わせに基づいて、均一の時間間隔で前記インスリン注入ポンプの最大インスリン送達速度を決定するように構成されている、コントローラと、を備える、システム。 - 前記コントローラはモデル予測制御アルゴリズム(MPC)を用いる、請求項12に記載のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/475,188 US11497851B2 (en) | 2017-03-31 | 2017-03-31 | Maintaining maximum dosing limits for closed loop insulin management systems |
US15/475,188 | 2017-03-31 | ||
PCT/US2018/025161 WO2018183689A1 (en) | 2017-03-31 | 2018-03-29 | Maintaining maximum dosing limits for closed loop insulin management systems |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020512153A true JP2020512153A (ja) | 2020-04-23 |
Family
ID=63671962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019553969A Pending JP2020512153A (ja) | 2017-03-31 | 2018-03-29 | 閉ループインスリン管理システムの最大投与量の維持 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11497851B2 (ja) |
EP (1) | EP3600037A4 (ja) |
JP (1) | JP2020512153A (ja) |
KR (1) | KR20190137844A (ja) |
CN (1) | CN110868927B (ja) |
AU (1) | AU2018243290A1 (ja) |
BR (1) | BR112019020316A2 (ja) |
CA (1) | CA3058440A1 (ja) |
RU (1) | RU2752597C2 (ja) |
TW (1) | TW201901604A (ja) |
WO (1) | WO2018183689A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1762259B1 (en) | 2005-09-12 | 2010-09-08 | Unomedical A/S | Inserter for an infusion set with a first and second spring units |
WO2012123274A1 (en) | 2011-03-14 | 2012-09-20 | Unomedical A/S | Inserter system with transport protection |
AU2020279722A1 (en) | 2019-05-20 | 2021-11-18 | Unomedical A/S | Rotatable infusion device and methods thereof |
EP4039293A1 (en) * | 2021-02-05 | 2022-08-10 | Insulet Corporation | Techniques and devices for adaptation of maximum drug delivery limits |
US20230040677A1 (en) * | 2021-08-03 | 2023-02-09 | Tandem Diabetes Care, Inc. | Systems and methods for automated insulin delivery response to meal announcements |
WO2023072306A1 (zh) * | 2021-10-25 | 2023-05-04 | 上海移宇科技有限公司 | 闭环人工胰腺胰岛素输注控制系统 |
WO2023070245A1 (en) * | 2021-10-25 | 2023-05-04 | Medtrum Technologies Inc. | Closed-loop artificial pancreas insulin infusion control system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010524639A (ja) * | 2007-04-25 | 2010-07-22 | メドトロニック ミニメド インコーポレイテッド | 閉ループ/半閉ループ治療修正システム |
JP2012502693A (ja) * | 2008-09-15 | 2012-02-02 | デカ・プロダクツ・リミテッド・パートナーシップ | 流体送達のためのシステムおよび方法 |
JP2016540564A (ja) * | 2013-12-05 | 2016-12-28 | ライフスキャン・インコーポレイテッドLifescan,Inc. | 糖尿病管理用ボーラス投与フィードバック |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6827702B2 (en) * | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US8152789B2 (en) | 2001-10-23 | 2012-04-10 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
GB0206792D0 (en) * | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
WO2005061041A1 (en) | 2002-10-11 | 2005-07-07 | Becton, Dickinson And Company | Insulin delivery system with sensor |
US7276029B2 (en) | 2003-08-01 | 2007-10-02 | Dexcom, Inc. | System and methods for processing analyte sensor data |
WO2009048462A1 (en) | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
EP1881786B1 (en) | 2005-05-13 | 2017-11-15 | Trustees of Boston University | Fully automated control system for type 1 diabetes |
US7704226B2 (en) * | 2005-11-17 | 2010-04-27 | Medtronic Minimed, Inc. | External infusion device with programmable capabilities to time-shift basal insulin and method of using the same |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
DK2171568T3 (en) * | 2007-06-29 | 2018-08-27 | Hoffmann La Roche | USER INTERFACE FEATURES FOR AN ELECTRONIC DEVICE |
WO2009004627A2 (en) | 2007-07-02 | 2009-01-08 | Medingo Ltd. | A device for drug delivery |
GB2466183A (en) | 2008-12-09 | 2010-06-16 | Cambridge Entpr Ltd | Closed loop diabetes management system |
WO2010099313A1 (en) | 2009-02-25 | 2010-09-02 | University Of Virginia Patent Foundation | Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US20100286653A1 (en) * | 2009-05-08 | 2010-11-11 | Axsol Incorporated, DBA Acess Solutions | Remote control device for use with insulin infusion systems |
WO2010135670A2 (en) | 2009-05-22 | 2010-11-25 | Abbott Diabetes Care Inc. | Safety layer for integrated insulin delivery system |
US8257300B2 (en) | 2009-05-22 | 2012-09-04 | Abbott Diabetes Care Inc. | Safety features for integrated insulin delivery system |
EP2432377A1 (en) | 2009-05-22 | 2012-03-28 | Abbott Diabetes Care, Inc. | Usability features for integrated insulin delivery system |
EP4325520A3 (en) * | 2009-05-29 | 2024-05-15 | University Of Virginia Patent Foundation | System coordinator and modular architecture for open-loop and closed-loop control of diabetes |
EP2437731B1 (en) * | 2009-06-04 | 2017-12-27 | Roche Diabetes Care GmbH | Device and method for adjusting basal delivery profile |
CN107252508A (zh) | 2009-09-18 | 2017-10-17 | F·霍夫曼-拉罗氏股份公司 | 用于根据用户参数对单次剂量进行量化的装置、系统和方法 |
US20110098638A1 (en) | 2009-10-27 | 2011-04-28 | Medtronic Minimed, Inc. | Sensor-Augmented Medication Infusion System |
JP5750123B2 (ja) | 2010-02-11 | 2015-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物学的因子又は薬物を被検者に送達するためのシステム、装置及び方法 |
US8579879B2 (en) | 2010-02-19 | 2013-11-12 | Medtronic Minimed, Inc. | Closed-loop glucose control startup |
US10561785B2 (en) | 2010-06-22 | 2020-02-18 | Medtronic Minimed, Inc. | Method and/or system for closed-loop control of glucose to a treatment range |
US20110313680A1 (en) | 2010-06-22 | 2011-12-22 | Doyle Iii Francis J | Health Monitoring System |
EP2628115B1 (en) | 2010-10-12 | 2015-06-03 | The Regents of The University of California | Insulin delivery device |
US9878096B2 (en) | 2012-08-30 | 2018-01-30 | Medtronic Minimed, Inc. | Generation of target glucose values for a closed-loop operating mode of an insulin infusion system |
US9364609B2 (en) | 2012-08-30 | 2016-06-14 | Medtronic Minimed, Inc. | Insulin on board compensation for a closed-loop insulin infusion system |
US9849239B2 (en) | 2012-08-30 | 2017-12-26 | Medtronic Minimed, Inc. | Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system |
US9907909B2 (en) | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
US10507284B2 (en) | 2013-01-14 | 2019-12-17 | The Regents Of The University Of California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type I diabetes applications |
US9795737B2 (en) | 2013-03-15 | 2017-10-24 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
WO2014172467A1 (en) * | 2013-04-16 | 2014-10-23 | Smartloop Llc | Discretionary insulin delivery systems and methods |
US10232113B2 (en) | 2014-04-24 | 2019-03-19 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for regulating insulin on board |
US10252002B2 (en) | 2014-08-01 | 2019-04-09 | Becton, Dickinson And Company | Continuous glucose monitoring injection device |
US10332633B2 (en) * | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range aggressiveness |
US10297350B2 (en) * | 2016-06-01 | 2019-05-21 | Roche Diabetes Care, Inc. | Risk-based control-to-range |
AU2019263490A1 (en) * | 2018-05-04 | 2020-11-26 | Insulet Corporation | Safety constraints for a control algorithm-based drug delivery system |
-
2017
- 2017-03-31 US US15/475,188 patent/US11497851B2/en active Active
-
2018
- 2018-03-29 CN CN201880035995.1A patent/CN110868927B/zh active Active
- 2018-03-29 TW TW107110871A patent/TW201901604A/zh unknown
- 2018-03-29 RU RU2019134803A patent/RU2752597C2/ru active
- 2018-03-29 AU AU2018243290A patent/AU2018243290A1/en not_active Abandoned
- 2018-03-29 KR KR1020197032336A patent/KR20190137844A/ko unknown
- 2018-03-29 EP EP18774776.1A patent/EP3600037A4/en not_active Withdrawn
- 2018-03-29 WO PCT/US2018/025161 patent/WO2018183689A1/en unknown
- 2018-03-29 BR BR112019020316A patent/BR112019020316A2/pt not_active Application Discontinuation
- 2018-03-29 CA CA3058440A patent/CA3058440A1/en active Pending
- 2018-03-29 JP JP2019553969A patent/JP2020512153A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010524639A (ja) * | 2007-04-25 | 2010-07-22 | メドトロニック ミニメド インコーポレイテッド | 閉ループ/半閉ループ治療修正システム |
JP2012502693A (ja) * | 2008-09-15 | 2012-02-02 | デカ・プロダクツ・リミテッド・パートナーシップ | 流体送達のためのシステムおよび方法 |
JP2016540564A (ja) * | 2013-12-05 | 2016-12-28 | ライフスキャン・インコーポレイテッドLifescan,Inc. | 糖尿病管理用ボーラス投与フィードバック |
Also Published As
Publication number | Publication date |
---|---|
RU2019134803A3 (ja) | 2021-04-30 |
TW201901604A (zh) | 2019-01-01 |
CN110868927B (zh) | 2023-05-23 |
US11497851B2 (en) | 2022-11-15 |
US20180280619A1 (en) | 2018-10-04 |
AU2018243290A1 (en) | 2019-10-24 |
WO2018183689A1 (en) | 2018-10-04 |
RU2019134803A (ru) | 2021-04-30 |
CA3058440A1 (en) | 2018-10-04 |
RU2752597C2 (ru) | 2021-07-29 |
KR20190137844A (ko) | 2019-12-11 |
BR112019020316A2 (pt) | 2020-06-09 |
EP3600037A4 (en) | 2020-12-23 |
EP3600037A1 (en) | 2020-02-05 |
CN110868927A (zh) | 2020-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2758210C2 (ru) | Система управления течением диабета с автоматическим управлением базальным введением инсулина и ручным управлением болюсным введением инсулина | |
JP2020512153A (ja) | 閉ループインスリン管理システムの最大投与量の維持 | |
US10188796B2 (en) | Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing | |
TWI643600B (zh) | 用於人工胰臟之封閉迴路控制的方法及系統 | |
CN104394907B (zh) | 在闭环控制器中处理手动推注或膳食事件的方法和系统 | |
TW201503921A (zh) | 用於人工胰臟之混合式控制至目標及控制至範圍模型預測控制的方法及系統 | |
KR20180109980A (ko) | 약물 전달 시스템을 위한 가시화 및 분석 도구 | |
TW201832788A (zh) | 使用於藥物遞送系統中之具有經改良安全性的音頻投藥 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20191211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191211 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210315 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221012 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230614 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230621 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230825 |